This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers a pivotal session on the new MASLD nomenclature, plus what the panelists found exciting and important about the developing class of triple agonists, at TLM 2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations of clinical trial results at TLM 2023.
Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green to discuss highlights of the recent TLM2023 conference.
Surfing NASH reviews the 2023 EASL SLD Summit in two interview sessions with meeting faculty members Sven Francque and Hannes Hagström. Co-host Jörn Schattenberg joins both conversations as a fellow presenter while Louise Campbell and Roger Green inject thought-provoking questions and perspectives to elicit a succinct snapshot of the event for our listeners.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. This discussion largely focuses on ideas around distinguishing the difference between NITs to qualify patients for trials versus to evaluate efficacy of drugs.
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. The group discusses loss aversion, screen fail rates, the future of FDA decision making and more.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.
